☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
United Therapeutics
United Therapeutics’ Tyvaso DPI Receives the US FDA’s Approval for Treatment of PAH and PH-ILD
May 24, 2022
PharmaShots Weekly Snapshots (June 14 - 18, 2021)
June 18, 2021
MannKind and United Therapeutics Reports the US FDA's Acceptance of NDA for Priority Review of Tyvaso DPI to Treat PAH and PH-ILD
June 17, 2021
PharmaShots Weekly Snapshots (May 31 - June 4, 2021)
June 4, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.